B. Alan Bottenberg, DO

Cardiometabolic Risk
Cardiometabolic Risk
PCSK9 Inhibitors for LDL Cholesterol Reduction: Emerging Clinical Perspectives
04/08/2016
Michael J. Bloch, MD; B. Alan Bottenberg, DO
Recently, therapy to reduce PCSK9 activity has been approved for use in those with cardiovascular disease who require additional LDL-C lowering despite the use of maximally tolerated statins.
04/08/2016
Cardiometabolic Risk
Cardiometabolic Risk
PCSK9 Inhibitors for LDL Cholesterol Reduction: Emerging Clinical Perspectives
04/08/2016
Michael J. Bloch, MD; B. Alan Bottenberg, DO
Recently, therapy to reduce PCSK9 activity has been approved for use in those with cardiovascular disease who require additional LDL-C lowering despite the use of maximally tolerated statins.
04/08/2016